Disease · MONDO_0024879
metastatic carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. metastatic carcinoma. Diseases, record MONDO_0024879. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024879
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| INALIMAREV (CEA, MUC-1, VACCINIA VIRUS) | CHEMBL2108609 | Vaccine component | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| SARGRAMOSTIM | CHEMBL1201670 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRINOTECAN HYDROCHLORIDE | CHEMBL3989514 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CSF2RA | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1438 | Drugs and targets |
| CSF2RB | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1439 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 1 | DNA topoisomerase I inhibitor | Phase 1 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TYMS | Thymidylate synthase | 1 | Thymidylate synthase inhibitor | Phase 1 | https://conductscience.org/library/genes/7298 | Drugs and targets |
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | Phase 1/2 | 51 | 2019-04-16 | Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer | SARGRAMOSTIM | Its record names the disease | ClinicalTrials.gov |
| NCT00544063 | Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer | Phase 1 | 33 | Unspecified Adult Solid Tumor, Protocol Specific | CAPECITABINE, IRINOTECAN HYDROCHLORIDE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: deaths from any cause | 1 of 25 | 0 of 26 | 51 | NCT00088413 | Trial comparisons |
Colorectal Cancer and Non-Colorectal Cancer Cohort vs Breast Cancer and Ovarian Cancer Cohort: Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v3.0 and v4.0 | 25 of 25 | 26 of 26 | 51 | NCT00088413 | Trial comparisons |
| Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: serious adverse events | 25 of 25 | 26 of 26 | 51 | NCT00088413 | Trial comparisons |
Colorectal Cancer Cohort vs Non-Colorectal Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Colorectal Cancer and Non-colorectal Cancer Cohort Post Vaccination | 3 of 9 | 6 of 9 | 18 | NCT00088413 | Trial comparisons |
Breast Cancer Cohort vs Ovarian Cancer Cohort: Number of Participants With an Positive Immune Response to Carcinoembryonic Antigen (CEA) Peptide and/or Protein in the Breast Cancer and Ovarian Cancer Cohorts Post Vaccination | 1 of 3 | 1 of 2 | 5 | NCT00088413 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024879
GET https://conductscience.org/api/diseases/v1/MONDO_0024879/drugs